LYMPHOMA, T-CELL
Clinical trials for LYMPHOMA, T-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR T-Cell therapy targets Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing an experimental cell therapy called MB-105 for adults with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is a CAR T-cell therapy, which involves modifying a patient's own immune cells to targ…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Apr 01, 2026 20:10 UTC
-
New drug aims to keep cancer at bay after risky transplant
Disease control Recruiting nowThis study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for lymphoma patients as trial tests pill to control resistant cancer
Disease control Recruiting nowThis study is testing an oral medication called golidocitnib for people with slow-growing T/NK-cell lymphomas that have come back or haven't responded to prior treatments. The goal is to see if this once-daily pill can effectively shrink tumors and control the disease. Researcher…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill challenges standard care for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing an experimental oral drug called soquelitinib against standard chemotherapy options for adults with specific aggressive T-cell lymphomas that have returned or not responded to prior treatment. About 150 participants will be randomly assigned to receive eithe…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC